Amgen stock steadies after Q2 2026 growth

Amgen stock is anchored by Q2 2026 revenue of $9.2 billion and diluted earnings per share of $4.12, both published in the companys second-quarter update. The figures give investors a fresh read on earnings power, even without a market-price datapoint in the available search results.

Q2 2026 numbers

In Amgens second-quarter report, product sales reached $8.9 billion in Q2 2026, up 12% from a year earlier on a reported basis. Total revenue of $9.2 billion also compared with the same period in 2025, while non-GAAP diluted EPS came in at $4.12 for the quarter.

The report also showed adjusted operating margin at 51.3% in Q2 2026, a level that signals strong conversion of sales into profit. For investors, that margin matters because it helps frame how much of the top-line growth can flow through to earnings.

Guidance stays central

Amgen kept its full-year 2026 outlook in view with revenue guidance of $35.0 billion to $36.0 billion and adjusted EPS guidance of $20.20 to $21.20. That range provides the main comparison point for the rest of the year because it sets a clear bar for both sales growth and profit delivery.

The same update also pointed to adjusted operating margin expectations in the high 40s for 2026, which gives a second reference point for how the business may perform over the next several quarters. The comparison is straightforward: Q2 adjusted operating margin was 51.3%, while the full-year frame is lower because it includes more of the companys usual seasonal and cost mix.

Pipeline and product mix

Among Amgens product lines, Repatha remains one of the most visible growth contributors in cardiovascular care. The company reported quarterly product sales across its portfolio, and Repatha continues to matter because it sits in a category where prescription growth can influence both revenue mix and margin quality.

Other key products, including Enbrel and Otezla, remain part of the companys base, but the latest quarterly lens is dominated by newer growth drivers and the ability to hold profitability above 50% on an adjusted basis in the quarter.

Amgen stock at a glance

Amgen stock is still best read through the combination of Q2 2026 sales, quarterly EPS, and the 2026 guidance range. The available search results do not provide a dated live quote, so the most current evidenced market context in this article is the companys reported 2026 financial guidance and quarterly operating profile.